DOI:
10.1055/s-00000020
Geburtshilfe und Frauenheilkunde
LinksClose Window
References
Gluz O, Nitz U, Liedtke C. et al.
Abstract GS5-06: No survival benefit of chemotherapy escalation in patients with pCR and “high-immune” triple-negative early breast cancer in the neoadjuvant WSG-ADAPT-TN trial.
Cancer Res 2019;
79 (4 Suppl.): GS5-06
Search in:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.